Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

3K3A-APC

Next Previous
Drug Profile

3K3A-APC

Alternative Names: 3K3A-activated protein C; 3K3A-APC non-anticoagulant mutant - ZZ Biotech; Activated-protein-C-analogue-University-of-Southern-California/Scripps-Research-Institute/ZZ-Biotech; Human-recombinant-3K3A-APC; Recombinant variant of human activated protein C (3K3A-APC)-ZZ-Biotech

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Socratech; The Scripps Research Institute; University of Southern California
  • Developer The Scripps Research Institute; University of Southern California; ZZ Biotech
  • Class Anti-infectives; Anti-inflammatories; Antithrombotics; Blood proteins; Enzyme precursors; Foot disorder therapies; Recombinant proteins; Serine endopeptidases; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Activated protein C receptor modulators; Factor V inhibitors; Factor VIII inhibitors; PAR 1 receptor modulators; PAR-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Ischaemic stroke
  • Phase I Diabetic foot ulcer
  • No development reported Stroke
  • Discontinued Neurological disorders; Septic shock

Most Recent Events

  • 23 Jun 2025 Dermatherix completes pre-IND meeting with US FDA to initiate phase II trial in Diabetic foot ulcer in Australia, before June 2025 (Dermatherix pipeline, June 2025)
  • 23 Jun 2025 Dermatherix plans a phase II trial in Diabetic Foot Ulcer in Australia (Dermatherix pipeline, June 2025)
  • 23 Jun 2025 Dermatherix plans a phase III registrational trial in Diabetic foot ulcer (Dermatherix pipeline, June 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top